Skip to content

2019 Colloquium Program

How has progress in molecular biology led to the discovery of new therapeutic targets? How have revolutionary treatment options been applied to various cancers? How will we select and evaluate these treatments in the futur?

Roadmap for progress in cancer treatment

Jean-Yves Blay (Lyon)

Malignant connective tissue tumors

Florence Duffaud (Marseille)

Endocrine tumors

Tamara Matisiak-Budnik (Nantes)

Lung cancers

Marie Wislez (Paris)

Urological cancers

Philippe Beuzeboc (Suresnes)

Are immunotherapies a real medical revolution?

Hervé Fridman (Paris)


Christine Longvert (Paris)

Gastrointestinal cancers

Julien Taieb (Paris)

Triple-negative breast cancers

Luis Teixeira (Paris)

From genetics to epigenetics: targeting DNA repair defects (PARP inhibitors and homologous recombination deficiency in ovarian cancer)

Pierre Combe (Paris)

Methods and perspectives

Christophe Tournigand (Paris)

Phase 1 clinical trials: new methods

Christophe Massard (Paris)

Phase 2 trials oriented by molecular profile

Christophe Le Tourneau (Paris)

The anatomic pathologist’s viewpoint

Frédéric Bibeau (Caen)

Liquid biopsies

Marc Ychou (Montpellier)

Tumor boards: molecular data

Pierre Laurent-Puig (Paris)

Lecture: Medical economics of innovative therapies in oncology

Claude Le Pen (Paris)

Closing lecture: Will artificial intelligence change medical practice?

Bernard Nordlinger (Paris)


Bernard Devulder